Compare AUID & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUID | CLGN |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 33.8M |
| IPO Year | N/A | N/A |
| Metric | AUID | CLGN |
|---|---|---|
| Price | $1.24 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 3.6M | 19.4K |
| Earning Date | 11-12-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,834,458.00 | ★ $2,475,000.00 |
| Revenue This Year | N/A | $1,617.28 |
| Revenue Next Year | N/A | $83.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 141.81 | ★ 280.77 |
| 52 Week Low | $1.15 | $1.31 |
| 52 Week High | $9.58 | $4.98 |
| Indicator | AUID | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 40.59 |
| Support Level | $1.15 | $1.92 |
| Resistance Level | $1.38 | $2.10 |
| Average True Range (ATR) | 0.23 | 0.15 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 7.89 | 27.27 |
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.